Chia Tai Tianqing reports Phase III data for anlotinib in NSCLC

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) reported data from the Phase III ALTER0303 trial in 437 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) who progressed after ≥2 lines of therapy showing that third-line treatment with once-daily 12 mg oral anlotinib (AL3818) on days 1-14 of each 21-day cycle met the primary endpoint of improving median overall survival (OS) vs. placebo (9.63 vs. 6.3 months, p=0.0018). Anlotinib also met the secondary endpoints of improving median progression-free survival (PFS) (5.37 vs. 1.4 months, p<0.0001), objective response rate (ORR) (9.2% vs. 0.7%, p<0.0001) and disease control rate (DCR) (81% vs. 37.1%, p<0.0001) vs. placebo. Data from the double-blind, Chinese trial were reported in an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago last month...